- Home
- DPG vs HELP Comparison
DPG vs HELP Comparison
Compare DPG & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | HELP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 535.3M | 281.4M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | DPG | HELP |
|---|---|---|
| Price | $14.29 | $5.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 107.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.45 | $5.15 |
| 52 Week High | $14.96 | $8.55 |
Technical Indicators
Market Signals| Indicator | DPG | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 37.78 |
| Support Level | $12.37 | N/A |
| Resistance Level | $14.68 | $7.28 |
| Average True Range (ATR) | 0.21 | 0.63 |
| MACD | -0.10 | -0.22 |
| Stochastic Oscillator | 26.14 | 3.24 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.